CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022
08/05/2022 - 08:38 AM
ROCKVILLE, Md. and BEIJING Aug. 5, 2022 8:00 A.M. EST on Friday , August 12th , 2022.
On the call, CASI's Chairman & CEO will provide an update on the Company's business and upcoming milestones. The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (International) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call. Confirmation #10169302.
This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (International) and enter 9173539 to access the replay.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China , the United States , and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China -based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China ) Co., Ltd., which is located in Beijing, China . The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China . More information on CASI is available at www.casipharmaceuticals.com .
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-report-second-quarter-2022-financial-results-and-host-conference-call-august-12-2022-301600771.html
SOURCE CASI Pharmaceuticals, Inc.
CASI Rankings
#174 Ranked by Stock Gains
CASI Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Rockville
About CASI
casi pharmaceuticals, inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in china, the united states, and internationally. the company's product pipeline includes evomela, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. its product pipeline also comprise cnct19, an autologous cd19 car-t investigative product for the treatment of patients with b-cell acute lymphoblastic leukemia (b-all) and b-cell non-hodgkin lymphoma; cid-103, an anti-cd38 monoclonal antibody being for the treatment of patients with multiple myeloma; zevalin, a cd20-directed radiotherapeutic antibody, to treat patients with nhl; and thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. in addition, the company of
